Company Description

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer.

The company’s lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.

It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs.

Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.

Mural Oncology plc

Country	Ireland
Founded	2013
Industry	Biotechnology
Sector	Healthcare
Employees	116
CEO	Caroline Loew

Contact Details

Address: 10 Earlsfort Terrace Dublin, D02 T380 Ireland
Phone	353 1 905 8020
Website	muraloncology.com

Stock Details

Ticker Symbol	MURA
Exchange	NASDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001971543
ISIN Number	IE000LK2BOB4
SIC Code	2834

Key Executives

Name	Position
Caroline J. Loew Ph.D.	President, Chief Executive Officer and Director
Adam D. Cutler B.A.	Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
Dr. Vicki L. Goodman M.D.	Chief Medical Officer
Maiken Keson-Brookes	Chief Legal Officer
Justin Levine	Head of Human Resources and Vice President of Human Resources

Latest SEC Filings

Date	Type	Title
Mar 25, 2025	8-K	Current Report
Mar 11, 2025	8-K	Current Report
Mar 11, 2025	424B5	Filing
Mar 11, 2025	S-8	Securities to be offered to employees in employee benefit plans
Mar 11, 2025	10-K	Annual Report
Mar 11, 2025	8-K	Current Report
Mar 5, 2025	144	Filing
Mar 5, 2025	144	Filing
Feb 24, 2025	144	Filing
Feb 14, 2025	SCHEDULE 13G/A	Filing

View All SEC Filings